The historical development, current status and future prospects of chlor-alkali electrolysis with oxygen depolarized cathodes (ODCs) are summarized. Over the last decades, membrane chlor-alkali technology has been optimized to such an extent that no substantial reduction of the energy demand can be expected from further process modifications. However, replacement of the hydrogen evolving cathodes in the classical membrane cells by ODCs allows for reduction of the cell voltage and correspondingly the energy consumption of up to 30%. This replacement requires the development of appropriate cathode materials and novel electrolysis cell designs. Due to their superior long-term stability, ODCs based on silver catalysts are very promising for oxygen reduction in concentrated NaOH solutions. Finite-gap falling film cells appear to be the technically most mature design among the several ODC electrolysis cells that have been investigated.

Background: A novel immunological approach to colon cancer therapy is the antibody targeting of the fibroblast activation protein (FAP), which is highly expressed by stroma cells of this tumour. Unconjugated sibrotuzumab (BIBH 1), which is a humanised version of the murine anti-FAP mAb F19, was investigated for its anti-tumour activity, safety and pharmacokinetics. Patients and Methods: Patients with metastatic colorectal cancer received weekly intravenous infusions of unconjugated sibrotuzumab at a dose of 100 mg over 12 scheduled weeks. The study was implemented as an open-label, uncontrolled, multicentre trial. Results: 25 patients were enrolled. Patients had one or more measurable lesions, predominantly liver lesions, at baseline. At least 8 repeated weekly infusions of sibrotuzumab in 17 evaluable patients did not result in complete or partial remission. Rather, ongoing tumour progression was noted in all patients except for 2 patients with stable disease. However, progressive disease was also observed post-study in these 2 patients who received 1 and 6 additional infusions, respectively, of sibrotuzumab. Sibrotuzumab exhibited 2-compartment pharmacokinetics with a dominant terminal phase and t1/2 ? = 5.3 ± 2.3 days. Adverse drug reactions (rigors/chills, nausea, flushing and one incidence of bronchospasm) were observed in 5 patients. Of the 24 patients given 2 or more infusions of sibrotuzumab, antibodies against sibrotuzumab were found in 3 patients (12.5%) after 4–12 infusions. Conclusions: Sibrotuzumab was well tolerated and safe. The minimal requirement for the continuation of this exploratory trial, of at least one complete or partial remission, or equivalently, of 4 patients with stable disease, was not met.

No abstract

A new concept for noncovalent immobilization of a ruthenium olefin metathesis catalyst is presented. The 2-isopropoxybenzylidene ligand of a Hoveyda-Grubbs carbene is further modified by an additional amino group (7) and immobilization is achieved by treatment with sulfonated polystyrene forming the corresponding ammonium salt. In this novel strategy for the immobilization of ruthenium-based metathesis catalysts, the amino group plays a two-fold role, being first an active anchor for immobilization and second, after protonation, activating the catalysts (electron donating to electron withdrawing activity switch). The polymeric support was prepared by precipitation polymerization which led to small bead sizes (0.2-2 microm) and large surface areas. Compared to commercial resins this tailor-made phase showed superior properties in immobilization of complex 7. This concept of immobilization was applied to glass-polymer composite megaporous Raschig rings. Ru catalyst 7 on Raschig rings was used under batch conditions in various metathesis reactions, including ring-closing (RCM), cross- (CM) and enyne metathesis, to give products of high chemical purity with very low ruthenium contamination levels (21-102 ppm). The same ring can be used for up to 6 cycles of metathesis.